Print version | PDF version | Send article | RSS feed

Novel agent for treatment of Parkinson's disease - Lu 02-750 - enters Lundbeck's development pipeline

02 Nov 2009 - H. Lundbeck A/S strengthens its pipeline of pharmaceuticals in clinical development by initiating phase I clinical studies with Lu 02-750 in order to investigate safety, tolerability and the pharmacokinetic profile of the drug in humans. The placebo-controlled study is expected to enrol around 100 healthy individuals.
 
Lu 02-750 is a dopaminergic agent acting on brain areas affected in Parkinson's disease. In animal models, the compound has demonstrated very convincing effects as compared to conventional treatments. Expectations are that the compound can offer Parkinson's patients a new and higher level of disease control.
 
"Focus at Lundbeck Research is to discover new innovative treatments that address unmet needs and offer clear benefits to the patients and we believe that Lu 02-750 has the potential to improve the treatment and life quality of patients suffering from Parkinson's disease", says Executive Vice President Peter Høngaard Andersen, Head of Research at Lundbeck and continues: "Lundbeck is actively pursuing external technologies and collaborations and Lu 02-750 has been discovered in close collaboration with Professor Håkan Wikström, Groningen University and Axon Biochemicals B.V."